FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895726712> ?p ?o ?g. }

• W2895726712 abstract "Background SB4, SB2, and SB5 are biosimilars of the reference etanercept (ETN), infliximab (INF), and adalimumab (ADA), respectively. Radiographic progression using the modified Total Sharp Score (mTSS) at week 0 and final week (week 52 for etanercept and adalimumab and week 54 for infliximab) was measured in phase III randomised, double-blind studies comparing efficacy and safety of biosimilar to its reference product. Objectives Assess and compare radiographic progression by disease activity states at week 24 (for etanercept and adalimumab) or week 30 (for infliximab) in terms of DAS28 from a pooled analysis of three biosimilar studies.1–3 Methods Patients with radiographic data from each phase III study were pooled and grouped based on their disease activity state (remission, low disease activity [LDA], moderate disease activity [MDA], and high disease activity [HDA]) at week 24 or 30 in terms of DAS28. The mean change in mTSS and the proportion of radiographic non-progressors of higher disease activity groups (LDA, MDA, and HDA) in reference to remission were summarised descriptively and odds ratios (OR) were compared using 95% confidence interval (CI) obtained from logistic model with baseline DAS28. Results A total of 1263 patients from phase III studies had radiographic assessment available and the results are summarised in table 1. Across all treatment groups, radiographic progression was the highest in HDA followed by MDA, LDA, and remission. In all treatments combined, the mean change in mTSS was 0.03, 0.38, 0.27, and 1.27 and the proportion of non-progressors was 79.7% (181/227), 78.1% (125/160), 74.1% (473/638), 58.4% (139/238) in remission, LDA, MDA, and HDA groups, respectively. In all treatments combined, compared to remission group, the estimated difference in mTSS was greater in HDA (1.15, 95% CI: 0.63–1.66) than MDA (0.20, 95% CI: −0.22–0.62) and LDA (0.36, 95% CI: −0.20–0.91) groups and the OR of the proportion of the non-progressors was the smallest in HDA (OR 0.40, 95% CI: 0.26–0.61) followed by MDA (OR 0.76, 95% CI: 0.52–1.10) and LDA (OR 0.90, 95% CI: 0.55–1.49) (figure 1). This trend was similarly observed in other treatment groups. Conclusions A pooled radiographic assessment data from three different biosimilar studies showed that radiographic progression was greater as disease activity worsened. References [1] Emery, et al. Rheumatology2017Dec;56(12):2093–2101. [2] Smolen, et al. Ann Rheum Dis2018Feb;77(2):234–240. [3] Weinblatt, et al. Arthritis Rheumatol2018Jan;70(1):40–48. Disclosure of Interest J. Smolen Grant/research support from: AbbVie, Janssen, MSD, Pfizer, Roche, and UCB, Consultant for: AbbVie, Amgen, AstraZeneca, Astro-Pharma, Celgene, GSK, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Novo Nordisk, Pfizer, Roche, Samsung Bioepis, Sanofi and UCB, M. Weinblatt Grant/research support from: Amgen, Bristol-Myers Squibb, Crescendo Bioscience, and Sanofi, Consultant for: AbbVie, Amgen, Novartis, Roche, GlaxoSmithKline, Merck, Samsung, Crescendo Bioscience, and AstraZeneca, and Bristol-Myers Squibb, Lilly, and Pfizer, P. Emery Consultant for: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Samsung, Sandoz and Lilly, E. Keystone Consultant for: Abbott, AstraZeneca, Bristol-Myers Squibb, Crescendo Bioscience, F. Hoffmann-La Roche, Genentech, Janssen, Lilly, Merck, Pfizer, UCB, Samsung Bioepis, M. Genovese Consultant for: Samsung, Merck, Abbvie, Amgen, BI, J. Vencovsky Consultant for: Samsung Bioepis, Biogen, G. Myung Employee of: Samsung Bioepis, E. Hong: None declared, I. Baek Employee of: Samsung Bioepis, S. Lee Employee of: Samsung Bioepis, J. Ghil Employee of: Samsung Bioepis" @default.
• W2895726712 created "2018-10-12" @default.
• W2895726712 creator A5003819213 @default.
• W2895726712 creator A5006289845 @default.
• W2895726712 creator A5018678002 @default.
• W2895726712 creator A5035556723 @default.
• W2895726712 creator A5046036100 @default.
• W2895726712 creator A5047117557 @default.
• W2895726712 creator A5052973748 @default.
• W2895726712 creator A5063335273 @default.
• W2895726712 creator A5080646462 @default.
• W2895726712 creator A5091418647 @default.
• W2895726712 date "2018-06-01" @default.
• W2895726712 modified "2023-09-27" @default.
• W2895726712 title "THU0201 A pooled analysis of three tnf-Α inhibitor biosimilar studies in patients with rheumatoid arthritis comparing radiographic progression by disease activity states" @default.
• W2895726712 doi "https://doi.org/10.1136/annrheumdis-2018-eular.4382" @default.
• W2895726712 hasPublicationYear "2018" @default.
• W2895726712 type Work @default.
• W2895726712 sameAs 2895726712 @default.
• W2895726712 citedByCount "0" @default.
• W2895726712 crossrefType "proceedings-article" @default.
• W2895726712 hasAuthorship W2895726712A5003819213 @default.
• W2895726712 hasAuthorship W2895726712A5006289845 @default.
• W2895726712 hasAuthorship W2895726712A5018678002 @default.
• W2895726712 hasAuthorship W2895726712A5035556723 @default.
• W2895726712 hasAuthorship W2895726712A5046036100 @default.
• W2895726712 hasAuthorship W2895726712A5047117557 @default.
• W2895726712 hasAuthorship W2895726712A5052973748 @default.
• W2895726712 hasAuthorship W2895726712A5063335273 @default.
• W2895726712 hasAuthorship W2895726712A5080646462 @default.
• W2895726712 hasAuthorship W2895726712A5091418647 @default.
• W2895726712 hasBestOaLocation W28957267121 @default.
• W2895726712 hasConcept C126322002 @default.
• W2895726712 hasConcept C141071460 @default.
• W2895726712 hasConcept C156957248 @default.
• W2895726712 hasConcept C2777138892 @default.
• W2895726712 hasConcept C2777226972 @default.
• W2895726712 hasConcept C2777575956 @default.
• W2895726712 hasConcept C2779134260 @default.
• W2895726712 hasConcept C2779722408 @default.
• W2895726712 hasConcept C2780132546 @default.
• W2895726712 hasConcept C44249647 @default.
• W2895726712 hasConcept C59491497 @default.
• W2895726712 hasConcept C71924100 @default.
• W2895726712 hasConceptScore W2895726712C126322002 @default.
• W2895726712 hasConceptScore W2895726712C141071460 @default.
• W2895726712 hasConceptScore W2895726712C156957248 @default.
• W2895726712 hasConceptScore W2895726712C2777138892 @default.
• W2895726712 hasConceptScore W2895726712C2777226972 @default.
• W2895726712 hasConceptScore W2895726712C2777575956 @default.
• W2895726712 hasConceptScore W2895726712C2779134260 @default.
• W2895726712 hasConceptScore W2895726712C2779722408 @default.
• W2895726712 hasConceptScore W2895726712C2780132546 @default.
• W2895726712 hasConceptScore W2895726712C44249647 @default.
• W2895726712 hasConceptScore W2895726712C59491497 @default.
• W2895726712 hasConceptScore W2895726712C71924100 @default.
• W2895726712 hasLocation W28957267121 @default.
• W2895726712 hasOpenAccess W2895726712 @default.
• W2895726712 hasPrimaryLocation W28957267121 @default.
• W2895726712 hasRelatedWork W2314174082 @default.
• W2895726712 hasRelatedWork W2317545799 @default.
• W2895726712 hasRelatedWork W2334356229 @default.
• W2895726712 hasRelatedWork W2413115384 @default.
• W2895726712 hasRelatedWork W2739057829 @default.
• W2895726712 hasRelatedWork W2744797686 @default.
• W2895726712 hasRelatedWork W2748864731 @default.
• W2895726712 hasRelatedWork W2749276380 @default.
• W2895726712 hasRelatedWork W2754524590 @default.
• W2895726712 hasRelatedWork W2755795982 @default.
• W2895726712 hasRelatedWork W2899998920 @default.
• W2895726712 hasRelatedWork W2900514407 @default.
• W2895726712 hasRelatedWork W2910347821 @default.
• W2895726712 hasRelatedWork W2911188397 @default.
• W2895726712 hasRelatedWork W2949868377 @default.
• W2895726712 hasRelatedWork W2950589883 @default.
• W2895726712 hasRelatedWork W3033376052 @default.
• W2895726712 hasRelatedWork W3034371279 @default.
• W2895726712 hasRelatedWork W3048126481 @default.
• W2895726712 hasRelatedWork W3165658112 @default.
• W2895726712 isParatext "false" @default.
• W2895726712 isRetracted "false" @default.
• W2895726712 magId "2895726712" @default.
• W2895726712 workType "article" @default.